As Shares Fall 64 Percent to Near Low, Transgenomic Ponders Next Step | GenomeWeb

Transgenomic has had a tough time adjusting.

The company said it would save between $10 million and $12 million per year by refocusing its business and restructuring its operations, which was completed last month, but investors have continued to punish Transgenomic since it announced the plan in mid-November.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.